Safety Issues Not Dampening AbbVie Optimism For Humira Successors

AbbVie is optimistic that its JAK1 inhibitor upadacitinib and anti-IL23 candidate risankizumab can increase its autoimmune market share, doubting a thromboembolic class effect for JAK inhibitors.

tests

AbbVie Inc. remains optimistic, despite some outside safety concerns, that its late-stage immunology drug candidates can increase its market share in autoimmune disease at a time when its top-selling powerhouse Humira (adalimumab) is facing increased competition from both biosimilars and new branded agents.

AbbVie talked up a number of pipeline milestones expected in the second half of 2017 during its July 28 second...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Business

More from Scrip